Delhi Master Plan 2047 Puts Max, Fortis and Medanta Stocks in Focus

Delhi’s Master Plan 2047 is emerging as a potential growth trigger for listed hospital operators with a strong presence in the National Capital Region. Brokerages are particularly positive on Max Healthcare Institute, Fortis Healthcare and Global Health, which operates the Medanta hospital chain.

The Master Plan 2047 was unveiled by the Union Ministry of Housing and Urban Affairs on August 20. The long-term plan aims to guide Delhi’s development as the capital’s population is projected to reach around 3.2 crore by 2047. It includes plans for around 40 lakh new affordable homes, improved transport infrastructure and redevelopment across the city.

For the healthcare sector, the plan could create more opportunities to expand hospital capacity in a city where land availability is limited. According to a Jefferies note cited by Business Standard, the new planning framework could improve the productivity of hospital assets and allow operators to create additional capacity.

One of the key changes highlighted by analysts is the removal of height restrictions for healthcare facilities, subject to the required approvals and applicable building rules. Higher Floor Area Ratio (FAR) norms could also allow hospitals to build more capacity on existing or strategically located land.

These changes could lower the cost of developing hospital beds in land-constrained parts of Delhi and improve the long-term productivity of healthcare assets. Higher-density development around transit corridors could further improve the viability of large hospital projects.

Jefferies has maintained a ‘buy’ rating on Max Healthcare, Fortis Healthcare and Global Health, with potential upside of up to 23% from current levels, according to the report.

The impact, however, is not limited to Delhi alone. Better connectivity across the wider region could increase the catchment areas of hospitals and allow them to attract patients from neighbouring parts of the NCR. The direct effect of MPD 2047 applies to the National Capital Territory of Delhi, while Noida, Gurugram and Faridabad follow separate state-level planning frameworks. Analysts therefore expect these cities to benefit mainly through improved regional connectivity and wider patient catchment areas.

Max Healthcare and Medanta could be among the biggest beneficiaries because of their planned capacity additions in Delhi-NCR. Jefferies estimates that Max could add around 2,108 beds, representing a 55% increase over its existing capacity. Medanta is expected to add around 1,267 beds, equivalent to a 68% increase in its current capacity.

Medanta could also see an improvement in its earnings as some of its operational challenges ease. PL Capital expects the company’s EBITDA to grow at around 24% annually between FY26 and FY29, supported by improvements at its Lucknow unit and the ramp-up of its Noida facility.

PL Capital has a ‘buy’ rating on Global Health and a target price of ₹1,750 per share, according to Business Standard. Anand Rathi has also maintained a ‘buy’ view on Max Healthcare, expecting its revenue and EBITDA to grow at around 18% annually between FY26 and FY28.

The development highlights how changes in urban planning can have a direct impact on listed companies. For healthcare operators, additional development rights, higher building potential and better connectivity could create room for new beds and larger facilities.

For investors watching Delhi-NCR stocks, the Master Plan 2047 therefore offers another long